Breezula - what's the consensus?
    Research/Science 6/3/2021

    At a glance
    In this general discussion post, the primary subjects mentioned are
    💧 Breezula (topical)
    the tone is 😐 neutral with mixed opinions results.

    Other terms

    People are discussing Breezula, a hair loss treatment, with mixed opinions on its value for the cost. Some are interested in it, while others think it's not worth the money.
    View this post in the Community →

    Similar Community Posts Join

    5 / 192 results

      community So we’re just ok with taking a research chemical now?

      in Treatment  181 upvotes 3 years ago
      The conversation discusses the use of RU58841, a non-FDA approved research chemical for hair loss, with mixed opinions on its safety and effectiveness. Some users are willing to try it as a last resort after other treatments like Minoxidil and Finasteride failed, while others express concerns about potential long-term side effects and lack of official research.

      community PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance

      in Research/Science  123 upvotes 11 months ago
      The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

      community The New, Improved CB-03-01/Setipiprant Group Buy

       27 upvotes 8 years ago
      The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.

      community Binding affinity of pyrilutamide!

      in Update  168 upvotes 2 years ago
      Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

    Related Research

    6 / 10 results